Pan-European Sarcoma Trials:Moving Forward in a Climate of Increasing Economic and Regulatory Pressure.

Advances in sarcoma treatment are largely based on investigator-initiated, multicentric and interdisciplinary clinical trials. The EU's Good Clinical Practice Directive 2001/20/EC, effective since 2004, was meant to harmonize the conditions for clinical trials across Europe, but, instead, the challe...

Descripción completa

Detalles Bibliográficos
Publicado en:Sarcoma Vol. 2007; pp. 1 - 8
Autores principales: Carrle, Dorothe, Dantonello, Tobias, Bielack, Stefan S.
Formato: Journal Article
Publicado: Wiley-Blackwell 2007
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=28652682&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 28652682
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        1357714X
        57R
      jtl: Sarcoma
      issn: 1357714X
      maglogo: Y
    pubinfo:
      dt: 2007
      vid: 2007
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        28652682
        10.1155/2007/76405
        28652682
      ppf: 1
      ppct: 7
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Pan-European Sarcoma Trials:Moving Forward in a Climate of Increasing Economic and Regulatory Pressure.
      aug:
        au:
          Carrle, Dorothe
          Dantonello, Tobias
          Bielack, Stefan S.
        affil: Klinikum Stuttgart, Olgahospital, Paediatrics 5 (Oncology, Haematology, Immunology), D-70176 Stuttgart, Germany
      sug:
      ab: Advances in sarcoma treatment are largely based on investigator-initiated, multicentric and interdisciplinary clinical trials. The EU's Good Clinical Practice Directive 2001/20/EC, effective since 2004, was meant to harmonize the conditions for clinical trials across Europe, but, instead, the challenge of initiating and running multinational, noncommercial clinical trials has become greater than ever. Institutions participating in existing noncommercial Pan-European studies are struggling to cope with increased administrative and financial burdens, and few new studies are initiated any more. The aim of a conference entitled ‘Pan-European Sarcoma Trials: Moving Forward in a Climate of Increasing Economic and Regulatory Pressure,’ held in Stuttgart, Germany, 30 November-2 December 2006 as part of the European Science Foundation's ECT-program, was not only to provide an overview of currently active and plannedmultinational studies on osteo-, Ewing's, and soft tissue sarcoma, but also to draw on areas of synergy between various established sarcoma groups in Europe to define plausible survival strategies for collaborative, interdisciplinary, patient-oriented research.
      pubtype: Academic Journal
      doctype: Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N